Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AKBA
  • CUSIP: N/A
  • Web: www.akebia.com
Capitalization:
  • Market Cap: $321.53 million
  • Outstanding Shares: 18,300,000
Average Prices:
  • 50 Day Moving Avg: $15.56
  • 200 Day Moving Avg: $13.09
  • 52 Week Range: $7.16 - $17.81
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $50.92 million
  • Price / Sales: 6.31
  • Book Value: $1.34 per share
  • Price / Book: 13.11
Profitability:
  • EBIDTA: ($140,360,000.00)
  • Return on Equity: -218.74%
  • Return on Assets: -52.65%
Debt:
  • Current Ratio: 1.83%
  • Quick Ratio: 1.83%
Misc:
  • Average Volume: 458,975 shs.
  • Beta: 0.98
  • Short Ratio: 4.73
 

Frequently Asked Questions for Akebia Therapeutics (NASDAQ:AKBA)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its earnings results on Tuesday, August, 8th. The company reported ($0.53) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.89) by $0.36. The business earned $28.52 million during the quarter, compared to analyst estimates of $26.50 million. View Akebia Therapeutics' Earnings History.

When will Akebia Therapeutics make its next earnings announcement?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Akebia Therapeutics.

Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?

6 brokers have issued 1-year price targets for Akebia Therapeutics' shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate Akebia Therapeutics' stock price to reach $22.83 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.

What are analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/14/2017)
  • 2. Aegis analysts commented, "We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA." (6/30/2017)

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:

  • Muneer A. Satter J.D., Independent Chairman of the Board
  • John P. Butler, President, Chief Executive Officer, Director
  • Jason A. Amello, Chief Financial Officer, Senior Vice President, Treasurer
  • Nicole R. Hadas, Senior Vice President, General Counsel, Secretary
  • Michel Dahan, Senior Vice President and Chief Business Officer
  • Rita Jain M.D., Senior Vice President, Chief Medical Officer
  • Karen Tubridy, Senior Vice President, Chief Development Officer
  • Scott A. Canute, Independent Director
  • Michael D. Clayman M.D., Independent Director
  • Maxine Gowen Ph.D., Independent Director

Who owns Akebia Therapeutics stock?

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (19.27%), Vanguard Group Inc. (7.85%), First Manhattan Co. (6.49%), FMR LLC (5.67%), Renaissance Technologies LLC (5.60%) and State Street Corp (5.17%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Citadel Advisors LLC, Eagle Asset Management Inc., Russell Investments Group Ltd., Piermont Capital Management Inc., Tudor Investment Corp ET AL, California State Teachers Retirement System and ProShare Advisors LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?

Akebia Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Numeric Investors LLC, State Street Corp, Crawford Lake Capital Management LLC, Goldman Sachs Group Inc. and EAM Investors LLC. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy Akebia Therapeutics stock?

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of Akebia Therapeutics stock can currently be purchased for approximately $17.57.


MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.83 (29.96% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/16/2017Royal Bank Of CanadaReiterated RatingOutperform$28.00LowView Rating Details
8/9/2017HC WainwrightReiterated RatingBuy$24.00HighView Rating Details
6/30/2017AegisReiterated RatingBuyHighView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 -> $21.00HighView Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/AView Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$24.00 -> $16.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Earnings History by Quarter for Akebia Therapeutics (NASDAQ AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.56)N/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.53)$26.50 million$28.52 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.15)($1.15)$16.50 million$20.87 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.77($0.99)$125.00 million$1.54 millionViewListenView Earnings Details
11/9/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.57)($0.95)$6.00 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.43)($0.70)$9.00 millionViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.34)($0.39)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-2.68 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Akebia Therapeutics (NASDAQ:AKBA)
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 57.62%
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Michel DahanSVPSell5,000$15.00$75,000.00View SEC Filing  
7/5/2017Muneer A SatterDirectorBuy1,034,482$14.50$14,999,989.00View SEC Filing  
7/3/2017Duane NashDirectorSell990$14.27$14,127.30View SEC Filing  
7/3/2017Nicole R. HadasSVPSell1,554$14.26$22,160.04View SEC Filing  
4/3/2017Duane NashDirectorSell991$9.20$9,117.20View SEC Filing  
4/3/2017Nicole R HadasSVPSell1,556$9.18$14,284.08View SEC Filing  
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.80View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Akebia Therapeutics (NASDAQ:AKBA)
Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
Source:
DateHeadline
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 9:08 AM
finance.yahoo.com logoEx-Akebia employee suspected of insider trading re-arrested
finance.yahoo.com - September 22 at 7:42 PM
americanbankingnews.com logoRoyal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - September 16 at 7:18 AM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM
seekingalpha.com logoAkebia (AKBA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 9:53 PM
finance.yahoo.com logoUltragenyx's Burosumab Positive in Phase II for XLH and TIO
finance.yahoo.com - September 12 at 3:54 PM
businesswire.com logoAkebia Reports Inducement Grant Under NASDAQ Listing Rule ... - Business Wire (press release)
www.businesswire.com - September 9 at 3:31 PM
finance.yahoo.com logoWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Surge - Yahoo Finance
finance.yahoo.com - September 6 at 3:38 PM
finance.yahoo.com logoAkebia to Present at Upcoming Investor Conferences
finance.yahoo.com - September 5 at 4:56 PM
finance.yahoo.com logoWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
finance.yahoo.com - September 5 at 4:56 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - September 3 at 11:22 PM
msn.com logoFDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
www.msn.com - August 30 at 4:26 PM
zacks.com logoStrength Seen in Catalent (CTLT): Stock Soars 13.9%
www.zacks.com - August 30 at 4:26 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 10:58 AM
finance.yahoo.com logoFeatured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
finance.yahoo.com - August 23 at 3:44 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) SVP Sells $75,000.00 in Stock
www.americanbankingnews.com - August 17 at 8:32 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - August 17 at 12:44 AM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 14 at 8:34 PM
finance.yahoo.com logoAkebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017
finance.yahoo.com - August 14 at 4:03 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Posts Earnings Results, Beats Expectations By $0.36 EPS
www.americanbankingnews.com - August 9 at 4:08 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - August 9 at 7:40 AM
businesswire.com logoAkebia Announces Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 8 at 8:42 PM
finance.yahoo.com logoAkebia Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 8:42 PM
finance.yahoo.com logoAkebia Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 8:42 PM
businesswire.com logoAkebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - August 4 at 9:10 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 10:44 AM
americanbankingnews.com logoZacks Investment Research Upgrades Akebia Therapeutics, Inc. (NASDAQ:AKBA) to "Hold"
www.americanbankingnews.com - August 1 at 7:46 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM
finance.yahoo.com logoETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:34 PM
americanbankingnews.com logoBidaskClub Downgrades Akebia Therapeutics, Inc. (NASDAQ:AKBA) to Sell
www.americanbankingnews.com - July 23 at 8:08 PM
reuters.com logoEx-Akebia employee faces losing bail in insider trading case - Reuters
www.reuters.com - July 20 at 10:08 PM
finance.yahoo.com logoEx-Akebia employee faces losing bail in insider trading case
finance.yahoo.com - July 20 at 10:08 PM
americanbankingnews.com logoZacks Investment Research Downgrades Akebia Therapeutics, Inc. (AKBA) to Sell
www.americanbankingnews.com - July 18 at 7:59 PM
finance.yahoo.com logoETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 5:32 PM
finance.yahoo.com logoAkebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : July 12, 2017
finance.yahoo.com - July 12 at 4:04 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Director Acquires $14,999,989.00 in Stock
www.americanbankingnews.com - July 11 at 7:52 PM
finance.yahoo.com logoAkebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017
finance.yahoo.com - July 11 at 4:57 PM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 10:40 AM
americanbankingnews.com logoAkebia Therapeutics, Inc. (AKBA) Given New $24.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 10 at 8:12 AM
finance.yahoo.com logoAkebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
finance.yahoo.com - July 6 at 5:02 PM
americanbankingnews.com logoInsider Selling: Akebia Therapeutics, Inc. (AKBA) Director Sells 990 Shares of Stock
www.americanbankingnews.com - July 6 at 1:34 PM
americanbankingnews.com logoNicole R. Hadas Sells 1,554 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock
www.americanbankingnews.com - July 6 at 1:34 PM
seekingalpha.com logoRevisiting Akebia Therapeutics - Seeking Alpha
seekingalpha.com - July 5 at 9:26 PM
americanbankingnews.com logoAegis Reaffirms "Buy" Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - June 30 at 12:25 PM
rttnews.com logoAkebia Therapeutics Prices Offering At $14.50/Share
www.rttnews.com - June 29 at 4:39 PM
streetinsider.com logoAkebia Therapeutics (AKBA) Prices 4M Share Offering at $14.50/Sh - StreetInsider.com
www.streetinsider.com - June 29 at 4:38 PM
finance.yahoo.com logoBiotech Movers: Akebia Shares Down After Pricing Stock Offering
finance.yahoo.com - June 29 at 4:38 PM
finance.yahoo.com logoBiotech Movers: Akebia Shares Down After Pricing Stock Offering
finance.yahoo.com - June 29 at 4:38 PM
finance.yahoo.com logoAkebia Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 29 at 1:58 AM
streetinsider.com logoAkebia Therapeutics (AKBA) to Offer Common Stock - StreetInsider.com
www.streetinsider.com - June 28 at 8:58 PM

Social

Chart

Akebia Therapeutics (AKBA) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff